Litigation Intelligence examines the patent position behind an infringement suit: which patent claims are asserted, what product or formulation is accused, and what the record can—and cannot—establish about the dispute.

Cases reviewed as filed and updated on the date shown on each brief. Each analysis identifies the asserted patent, accused product, forum, and the issue that matters beyond the docket.

Organon & Dermavant v. Dr. Reddy's August 2026 US 10,195,160 VTAMA® cream 1% D.N.J. No. 2:26-cv-11431 An ANDA formulation patent: whether the claimed MCT-based oil-in-water system, rather than the molecule itself, is what is being copied. Reframe Technologies LLC v. Robinhood Markets September 2026 US 7,552,870 Trading Network Resources District of Delaware 1:26-cv-01113 A network-resource trading patent: whether Robinhood’s financial infrastructure mirrors the claimed direct authorization and credit-settlement system for trading network access. ABC IP & Rare Breed Triggers v. Forced-Reset Trigger Sellers October 2026 US 10,514,223 + 8 asserted patents · FRT-15 E.D. Tex. MDL No. 3176 A 131+ suit campaign consolidated into one MDL: whether claims on a firearm-cycle-driven trigger reset reach competing designs, with early court rulings pointing in different directions. Cerinet USA v. ATSC 3.0 Supply Chain October 2026 US 9,253,428 ATSC 3.0 / NextGen TV 12 U.S. suits Venues being confirmed A broadcast-signaling patent asserted against 13 defendants: whether claims drafted around a DVB-T2 and LTE hybrid metadata channel read onto the finalized ATSC 3.0 bootstrap. Headwater Research LLC v. Platform, Messaging and Cloud Providers October 2026 10 patents One 2009 provisional family W.D. & E.D. Tex. e.g. 7:26-cv-00338 In-force network usage control patents asserted in different subsets per defendant: whether later claims are truly entitled to the January 2009 priority date. Valtrus Innovations v. Data-Center Operators October 2026 US 6,854,287 + US 6,868,682 · Cooling (expired) E.D. Tex. MDL No. 3190 Two expired HP-origin cooling patents, so damages only: whether operators’ equipment meters cooling flow individually and arranges control in an escalating agent hierarchy, with supplier Vertiv leading the pushback. Near Field Electronics v. Retailers October 2026 US 6,691,201 + 4 expired · NXP PN512 chip E.D. Tex. Sherman Div. · 29-case sample Five expired patents aimed at merchants’ contactless payment terminals over one NFC chip: whether “plurality of signaling protocols” stretches beyond USB and PS/2 to the chip’s host interfaces. Shionogi v. Sandoz, Cipla, Azurity & Apotex October 2026 US 12,599,586 + 3 more · RADICAVA ORS® D.N.J. 2:26-cv-08842 et al. Four ANDA suits where formulation, pharmacokinetic and meal-dependent dosing patents surround an established ALS drug: whether the protection that matters is how edaravone is taken, not the molecule. AbbVie & Allergan v. Micro Labs, Hetero, Macleods & Apotex October 2026 US 12,622,897 + US 12,661,341 · QULIPTA® D.N.J. 3:26-cv-10378 et al. Two method-of-treatment dosing patents (OATP inhibitors, hepatic impairment): whether a generic’s proposed labeling would encompass the claimed dosing approaches. Eli Lilly v. Fourteen Generic Manufacturers October 2026 10 patents Mounjaro® / Zepbound® D. Del. 1:26-cv-00972 to -00988 A ten-patent tirzepatide portfolio running from molecule to formulation to dosing regimen: a generic entrant must clear every layer, not a single patent.